Skip to content

Cannabis for anxiety

Studies whose primary subject is both Cannabis and Anxiety, with an evidence synthesis read across the most-cited and most recent of them.

State of the evidence

Synthesized

Synthesized from 22 studies in the library · AI-generated, grounded in the abstracts below

Found by searching the library for Cannabis, marijuana, THC, tetrahydrocannabinol, Anxiety, generalized anxiety disorder, then ranked by relevance.

The research is mixed and depends heavily on the specific cannabinoid and dose. CBD shows anxiolytic properties in several human experimental and review studies, whereas THC commonly produces anxiogenic effects, especially at higher doses; cannabis containing both THC and CBD tends to produce less anxiety than THC-dominant products. Observational and preclinical evidence also links cannabis use to anxiety symptoms and anxiety-like behavior, but samples are often small, short-term, or in animals, so durability and clinical benefit remain uncertain.

Evidence by study

Direction is which way each study's own result points, not our rating of the study. All 25 matching studies were reviewed; the 22 that directly address the question are shown here.

What the directions mean
Supports:
the study found the intervention worked, or its hypothesis held.
Opposes:
it found the opposite, no benefit or a harm.
No effect:
no significant difference either way.
Mixed:
effects in both directions within the same study.
Unclear:
the abstract does not report a direction.
Study Design Sample size Direction Finding
Distinct Effects of Δ9-Tetrahydrocannabinol and Cannabidiol on Neural Activation During Emotional Processing 2009 RCT 15 Mixed THC increased anxiety and autonomic arousal to fearful faces, while CBD showed a trend toward reduced anxiety and dampened limbic activation.
Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug 2006 review Supports Animal and human studies suggest CBD has anxiolytic-like effects and may reduce THC-induced anxiety and psychotic symptoms.
Modulation of Mediotemporal and Ventrostriatal Function in Humans by Δ9-Tetrahydrocannabinol 2009 RCT 15 Opposes THC increased anxiety, psychotic symptoms, intoxication, and sedation, whereas CBD had no significant effect on these measures.
Medicinal cannabis for psychiatric disorders: a clinically-focused systematic review 2020 systematic review Mixed Evidence for cannabinoid-based psychiatric treatment is nascent and insufficient to recommend it, though isolated studies give tentative support for CBD in social anxiety.
Modulation of effective connectivity during emotional processing by Δ9-tetrahydrocannabinol and cannabidiol 2009 RCT 15 Supports CBD, but not THC, disrupted forward connectivity between the amygdala and anterior cingulate during fearful face processing, proposed as a correlate of its anxiolytic properties.
Cannabis, a cause for anxiety? A critical appraisal of the anxiogenic and anxiolytic properties 2020 systematic review Mixed Acute CBD reduced anxiety without anxiogenic effects at higher doses, while THC commonly produced anxiogenic responses, especially at higher doses.
Mitigation of post‐traumatic stress symptoms by Cannabis resin: A review of the clinical and neurobiological evidence 2012 review Supports Cannabis resin was reported to dramatically reduce PTSD symptoms including panic and anxiety in a case report, with preclinical evidence for endocannabinoid involvement in stress regulation.
Δ-9-Tetrahydrocannabinol and Cannabidiol produce dissociable effects on prefrontal cortical executive function and regulation of affective behaviors 2018 experimental study Mixed Intra-prefrontal THC produced anxiogenic effects, while CBD blocked THC's anxiogenic properties but impaired some cognitive functions.
What are the psychological effects of using synthetic cannabinoids? A systematic review 2019 systematic review Opposes Synthetic cannabinoid users showed elevated symptomatology including paranoia compared with natural cannabis and non-users, though evidence on anxiety specifically was limited.
Cannabis‐induced Koro in Americans 2001 case series 3 Opposes Three men experienced cannabis-induced Koro, an acute panic reaction, after smoking marijuana in novel settings or atypical ways.
Patterns, Trends, and Meanings of Drug Use by Dance-drug Users in Edinburgh, Scotland 2004 cross-sectional survey 124 Opposes At least 40% of dance-drug users reported anxiety, nausea, and paranoia, though cannabis-specific effects were not isolated.
Rates and correlates of cannabis-associated psychotic symptoms in over 230,000 people who use cannabis 2022 observational cohort 233475 Opposes Lifetime acute cannabis-associated psychotic symptoms requiring emergency treatment occurred in 0.47% of users, with elevated risk among those with pre-existing anxiety diagnoses.
Effects of Chronic Exposure to Low-Dose delta-9-Tetrahydrocannabinol in Adolescence and Adulthood on Serotonin/Norepinephrine Neurotransmission and Emotional Behavior 2020 RCT Opposes Chronic low-dose THC exposure in adolescence and adulthood produced an anxious phenotype in the elevated plus maze and reduced serotonergic neural activity.
Cannabis containing equivalent concentrations of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) induces less state anxiety than THC-dominant cannabis 2022 RCT 26 Mixed THC and THC/CBD both increased state anxiety versus placebo, but THC/CBD produced less anxiety than THC alone; CBD's counteracting effect was absent in those with high baseline anxiety.
Beyond the Diagnostic Binary: A Translational Use of the Research Domain Criteria to Improve the Measurement of Anxiety in the Context of Cannabis Use 2026 mixed methods 30 Unclear Both medical and recreational consumers showed clinically significant anxiety symptoms, and the authors argue for a transdiagnostic framework to study when cannabis induces or reduces anxiety.
Beyond symptom change: a qualitative descriptive study of reported quality of life experiences among adults prescribed medicinal cannabis for anxiety disorders 2026 qualitative 9 Supports Participants reported perceived improvements in quality of life, sleep, emotional regulation, and daily functioning, describing medicinal cannabis as a tool for managing rather than eliminating anxiety.
Long-term effects of adolescent THC exposure on anxiety-like behavior and cognitive function in male rats 2026 RCT Opposes Adolescent THC exposure produced anxiety-like behavior in the elevated plus maze and impaired novelty preference in young adulthood.
Cannabis vaping and mental health: The association of Δ-9-tetrahydrocannabinol and cannabidiol with anxiety and depressive symptoms-Findings from the United States National Youth Tobacco Survey (2021-2023). 2026 observational 69899 Opposes Adolescents who vaped THC only or CBD only had higher odds of anxiety symptoms than non-vapers, and exclusive CBD vaping was associated with higher odds of anxiety than exclusive THC vaping.
Personality, not cognition, distinguishes chronic ayahuasca and cannabis users from non-users 2026 cross-sectional 219 No effect Abstinent chronic cannabis users showed no significant neuropsychological deficits and no current psychopathological symptoms despite higher lifetime mood and anxiety disorder prevalence.
Involvement of Adenosine A2A Receptors in Anxiety-Like Behaviors in Tetrahydrocannabinol-Treated Mice. 2026 experimental study Opposes THC induced anxiety-like behavior, with gene expression suggesting interaction between adenosinergic and cannabinoidergic systems.
Cannabis Use is Related to Anhedonia in Adolescents With Diverse Mood and Anxiety Symptoms. 2025 cross-sectional 153 Opposes Adolescents who used cannabis reported worse anticipatory anhedonia than those who never used or tried cannabis once, with more frequent use correlating with greater anhedonia.
Adolescent female rats are resistant to the affective and cognitive impacts of Δ9-tetrahydrocannabinol exposure despite long-lasting molecular and neuronal disturbances in the hippocampal-hypothalamic network. 2025 preclinical study No effect Adolescent female rats exposed to THC showed no long-term behavioral abnormalities including anxiety, despite enduring molecular and neural adaptations.

Points of agreement

  • CBD shows anxiolytic properties in several human experimental studies and reviews.
  • THC commonly produces anxiogenic effects, especially at higher doses.
  • Cannabis containing both THC and CBD tends to produce less anxiety than THC-dominant products.
  • Preclinical studies frequently report anxiety-like behavior after THC exposure.

Conflicts

  • Some human studies find CBD reduces anxiety, while an adolescent survey found exclusive CBD vaping associated with higher odds of anxiety symptoms.
  • THC is predominantly anxiogenic in experimental studies, but some epidemiological evidence suggests anxiolytic effects from whole-plant cannabis or THC.
  • One preclinical study found no long-term anxiety effects in female rats, while others report anxiety-like behavior after adolescent THC exposure.

Gaps

  • Long-term durability of anxiolytic effects is largely unstudied.
  • Optimal dosing and THC:CBD ratios for anxiety are unclear.
  • Most human experimental studies use small samples of healthy, minimally cannabis-exposed men.
  • Blinding integrity and expectancy effects are rarely assessed.
  • Clinical populations with diagnosed anxiety disorders are underrepresented in controlled trials.
  • Sex differences and adolescent versus adult effects need further study.
Browse these studies in the library

Common questions

What does the research agree on about cannabis for anxiety?
  • CBD shows anxiolytic properties in several human experimental studies and reviews.
  • THC commonly produces anxiogenic effects, especially at higher doses.
  • Cannabis containing both THC and CBD tends to produce less anxiety than THC-dominant products.
  • Preclinical studies frequently report anxiety-like behavior after THC exposure.
Where do studies on cannabis for anxiety conflict?
  • Some human studies find CBD reduces anxiety, while an adolescent survey found exclusive CBD vaping associated with higher odds of anxiety symptoms.
  • THC is predominantly anxiogenic in experimental studies, but some epidemiological evidence suggests anxiolytic effects from whole-plant cannabis or THC.
  • One preclinical study found no long-term anxiety effects in female rats, while others report anxiety-like behavior after adolescent THC exposure.
What is still unknown about cannabis for anxiety?
  • Long-term durability of anxiolytic effects is largely unstudied.
  • Optimal dosing and THC:CBD ratios for anxiety are unclear.
  • Most human experimental studies use small samples of healthy, minimally cannabis-exposed men.
  • Blinding integrity and expectancy effects are rarely assessed.
  • Clinical populations with diagnosed anxiety disorders are underrepresented in controlled trials.
  • Sex differences and adolescent versus adult effects need further study.
How we analyze this

This synthesis reads the 15 most-cited and 10 most recent studies whose primary subject is Cannabis for anxiety, up to 25 in all. The most-cited set anchors the established evidence, and the recent set surfaces work that is too new to have gathered citations yet.

A study qualifies only when Cannabis for anxiety or a known alias appears in its title or keywords, so broad reviews that mention it only in passing are left out. Each study is read from its abstract, strongest evidence first, and the summary reports the direction of the results along with any conflicts and gaps.

The full method, including what a person does and does not review, is on the methods page.

Ask your own question in the Research Synthesis Tool

53 articles · 16 from the last two years · 587,335 participants across 28 studies reporting sample size

Common study designs

review 6 systematic review 4 experimental study 4 observational cohort 4 randomized controlled trial 9

Research volume by year

Compare topics →

50 studies whose primary subject is cannabis for anxiety since 2004

Studies about cannabis for anxiety per year, 2004 to 2026, peaking at 8 in 2025 Bar chart: one bar per year, taller where more studies were published that year. 0 4 8 2005 2010 2015 2020 2025
2026 is partial
Show the numbers
Studies about cannabis for anxiety per year, 2004 to 2026, peaking at 8 in 2025
Year Studies
2004 1
2005 0
2006 1
2007 0
2008 0
2009 3
2010 0
2011 0
2012 1
2013 0
2014 1
2015 1
2016 0
2017 0
2018 3
2019 5
2020 6
2021 2
2022 3
2023 6
2024 1
2025 8
2026 8

Research

Synthesize the evidence →

Beyond the Diagnostic Binary: A Translational Use of the Research Domain Criteria to Improve the Measurement of Anxiety in the Context of Cannabis Use

Healthcare August 1, 2026 Nicole Ennis, Katie Kloss, Alyssa Flores

Introduction: Epidemiological data indicate that over half of people who consume cannabis report anxiety reduction as a reason for use. Anxiety is frequently cited as a primary motivation for cannabis use among both medical and recreational consumers. The lifetime prevalence of anxiety disorders in the United States is approximately 34% with more recent data suggesting that the figure may be as...

DOI: 10.3390/healthcare14152333 (opens in new tab)

Past-Year Psilocybin and Alcohol Co-Use: Associations With Mental Health Symptoms

Journal of Drug Issues July 1, 2026 Haley M Hummel, Alexia N Obrochta, David C. R. Kerr et al.

Interest has grown in the effects of psilocybin on mental health, but little is known about its naturalistic use alongside alcohol and its relationship to depression and/or anxiety symptoms. Data from the nationally-representative 2024 National Survey Investigating Hallucinogenic Trends of participants who did ( n = 1234) or did not ( n = 1607) report past-year psilocybin and alcohol co-use...

DOI: 10.1177/00220426261466154 (opens in new tab) Psilocybin Anxiety Cannabis Hallucinogen +8

Beyond symptom change: a qualitative descriptive study of reported quality of life experiences among adults prescribed medicinal cannabis for anxiety disorders

International Journal of Clinical Pharmacy June 9, 2026 Leah Roberts, Craig Cumming, C. Budgeon et al.

Anxiety disorders are among the most prevalent and disabling mental health conditions and are associated with impairments in quality of life (QoL). Previous studies have examined medicinal cannabis for anxiety and QoL using short-term follow-up or cross-sectional surveys. However, there is little longitudinal qualitative research examining how patients experience QoL changes. To explore the...

DOI: 10.1007/s11096-026-02176-2 (opens in new tab) Full text (opens in new tab)

Long-term effects of adolescent THC exposure on anxiety-like behavior and cognitive function in male rats

Psychopharmacology April 23, 2026 Josephine Sena Lumor, Henriette Nyberg, Elisabeth Nerem et al.

Abstract Rationale As cannabis legalization and decriminalization have expanded, it is increasingly perceived as a low-risk substance. Concurrently, the potency of cannabis products and the number of young adults seeking treatment for cannabis use disorder have risen markedly. A growing body of research links early onset, frequent use, and high potency cannabis products to a range of adverse...

DOI: 10.1007/s00213-026-07067-y (opens in new tab)

Cannabis vaping and mental health: The association of Δ-9-tetrahydrocannabinol and cannabidiol with anxiety and depressive symptoms-Findings from the United States National Youth Tobacco Survey (2021-2023).

Addiction (Abingdon, England) March 2026 Jack Chung, Daniel Stjepanović, Brandon Cheng et al.

Cannabis use is associated with psychiatric comorbidities, and the use of elta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) produces different neurophysiological and pharmacological effects. This study estimated the strength of associations between vaping of THC and CBD with depressive and anxiety symptoms in adolescents. Observational data were drawn from three years of the nationally...

DOI: 10.1111/add.70218 (opens in new tab) Full text (opens in new tab) Anxiety Depression Cannabis use Mental health +1

Personality, not cognition, distinguishes chronic ayahuasca and cannabis users from non-users

European Neuropsychopharmacology February 12, 2026 José Carlos Bouso, Óscar Andión, Sabela Fondevila Estévez et al.

The increasing interest in the therapeutic potential of psychedelics and cannabis underscores the need to understand their long-term neuropsychological and personality effects. This cross-sectional study compared regular users of ayahuasca (n = 69), cannabis (n = 56), and non-substance users (n = 94) on a battery of neuropsychological tasks and psychological questionnaires. Participants were...

DOI: 10.1016/j.euroneuro.2026.112782 (opens in new tab) Cannabis Ayahuasca Anxiety Clinical psychology +11

Involvement of Adenosine A2A Receptors in Anxiety-Like Behaviors in Tetrahydrocannabinol-Treated Mice.

Brain and Behavior February 1, 2026 Burçin Ün, Zeki Akarsakarya, Özlem Yorulmaz Özü et al.

Previous studies have suggested that adenosinergic system in the central nervous system may play a role in both behavioral changes and the physiopathology induced by Δ9-tetrahydrocannabinol (THC), and this is thought to be mediated by adenosine A2A receptors (A2ARs). However, the contribution of the adenosinergic system to the anxiety-like behaviors in response to THC in mice is not well...

DOI: 10.1002/brb3.71126 (opens in new tab) Full text (opens in new tab) Tetrahydrocannabinol Adenosine a2a receptors Anxiety‐like behaviors Hippocampus

Partydrogen im Überblick

Psychopharmakotherapie 2026 Antonia Bendau, Felix Betzler, Twyla Michnevich et al. 1 citation

Party drugs encompass a broad spectrum of legal and illegal psychoactive substances used in party settings such as clubs, festivals, raves or private gatherings to modulate mood, perception, social interaction and bodily states. Most commonly, alcohol and cannabis are consumed, followed by amphetamine, MDMA (“ecstasy”), cocaine and ketamine. Synthetic cathinones, GHB/GBL (“liquid ecstasy”),...

DOI: 10.52778/ppt20260001 (opens in new tab) Serotonergic MDMA Addiction Cannabis +16

Cannabis Use is Related to Anhedonia in Adolescents With Diverse Mood and Anxiety Symptoms.

JAACAP open December 1, 2025 Tram N B Nguyen, Benjamin A Ely, Aria Vitale et al.

Youth with depression use cannabis at high rates, and exposure to cannabinoids in adolescence has been shown to deleteriously alter the reward system. However, there has been sparse research on the link between adolescent cannabis use and anhedonia, a core symptom of depression and clinical manifestation of reward dysfunction. Here, in a sample of adolescents presenting predominantly with mood...

DOI: 10.1016/j.jaacop.2025.02.003 (opens in new tab) Full text (opens in new tab) Anxiety Cannabis Depression Anhedonia +1

Adolescent female rats are resistant to the affective and cognitive impacts of Δ9-tetrahydrocannabinol exposure despite long-lasting molecular and neuronal disturbances in the hippocampal-hypothalamic network.

Psychopharmacology November 1, 2025 Marta De Felice, Hanna J Szkudlarek, Matthew J Jones et al.

RATIONALE: Chronic cannabis during adolescence is associated with long-lasting pathological outcomes, and these effects can be remarkably different between the sexes. Preclinical studies in rodents demonstrated that sustained exposure to Δ9-tetrahydrocannabinol (THC), induces sex-specific pathophysiological outcomes. Thus, while males exhibit higher vulnerability to schizophrenia-like...

DOI: 10.1007/s00213-025-06817-8 (opens in new tab) Full text (opens in new tab) Anxiety THC Adolescence Females +5

Clinical trials

All cannabis for anxiety trials →